0.5 mg epinephrine
0.5 mg epinephrine: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: ARS Pharmaceuticals, Inc. (SPRY)
Development Pipeline (1)
| Company | Phase |
|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | Phase 2 |
Clinical Trials (1)
An Outpatient, Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
Frequently asked questions
Who is developing 0.5 mg epinephrine?
0.5 mg epinephrine is being developed by ARS Pharmaceuticals, Inc..
How many clinical trials involve 0.5 mg epinephrine?
BioSniper tracks 1 clinical trial involving 0.5 mg epinephrine.
Analyze ARS Pharmaceuticals, Inc. & 0.5 mg epinephrine with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company